CHIEF-HF: Improvement in Heart Failure Symptoms at 12 Wk With Canagliflozin vs Placebo

Source: Innovations in Heart Failure: Highlights and Insights From AHA 2021*
Download Slideset
November 13-15, 2021; Virtual
In this virtually conducted clinical trial, no physician visits occurred and data were collected via smart phone app.
Format: Microsoft PowerPoint (.ppt)
File Size: 214 KB
Released: December 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

From Clinical Care Options (CCO), expert commentary on new data in telehealth for heart failure management from AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 13, 2021 Expired: December 12, 2022

From Clinical Care Options (CCO), Dr. Lee Goldberg discusses clinical studies of novel therapies for heart failure management presented at AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 9, 2021 Expired: December 8, 2022

From Clinical Care Options (CCO), expert commentary on new data in heart failure management from AHA 2021

Lee R. Goldberg, MD, MPH, FACC Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 8, 2021 Expired: December 7, 2022

From AHA 2021, new analysis from EMPEROR-Preserved trial of empagliflozin in patients with “true” HFpEF, as reported by Clinical Care Options (CCO)

Released: December 2, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings